-$0.54 EPS Expected for Surrozen, Inc. (NASDAQ:SRZN) This Quarter

Brokerages forecast that Surrozen, Inc. (NASDAQ:SRZN – Get Rating) will report ($0.54) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Surrozen’s earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.46). The business is expected to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Surrozen will report full year earnings of ($2.31) per share for the current fiscal year, with EPS estimates ranging from ($2.60) to ($2.01). For the next year, analysts expect that the company will post earnings of ($1.48) per share, with EPS estimates ranging from ($1.48) to ($1.47). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Surrozen.

Surrozen (NASDAQ:SRZN – Get Rating) last announced its earnings results on Thursday, March 24th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.17.

Separately, Zacks Investment Research upgraded shares of Surrozen from a “sell” rating to a “hold” rating in a research report on Friday, April 22nd.

A number of hedge funds have recently bought and sold shares of SRZN. Column Group LLC grew its stake in Surrozen by 1.8% during the fourth quarter. Column Group LLC now owns 9,414,795 shares of the company’s stock worth $60,631,000 after buying an additional 166,666 shares during the period. Consonance Capital Management LP boosted its position in Surrozen by 249.8% during the 4th quarter. Consonance Capital Management LP now owns 3,497,500 shares of the company’s stock worth $22,359,000 after purchasing an additional 2,497,500 shares during the period. Harvard Management Co. Inc. acquired a new stake in Surrozen in the 3rd quarter valued at $5,854,000. Board of Trustees of The Leland Stanford Junior University purchased a new position in Surrozen in the third quarter valued at about $5,709,000. Finally, Trustees of Columbia University in the City of New York acquired a new position in shares of Surrozen during the third quarter worth about $5,090,000. 66.97% of the stock is owned by hedge funds and other institutional investors.

Surrozen stock opened at $2.57 on Monday. The stock’s 50-day moving average is $2.99. Surrozen has a 52 week low of $1.98 and a 52 week high of $14.00.

About Surrozen (Get Rating)

Surrozen, Inc, a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Featured Articles